Nitrofurantoin Glenmark Pharmaceuticals (Nitrofurantoin)

Nitrofurantoin exerts a bactericidal effect by entering bacterial cells and disrupting carbohydrate metabolism, which leads to the formation of toxic intermediates that damage bacterial DNA, proteins and cell‑wall synthesis. High concentrations in urine make it especially effective against common uropathogens.

The prescribed dose of Nitrofurantoin is determined by the treating clinician based on infection severity, renal function and individual patient characteristics. Dosage regimens are individualized and must follow the prescriber’s specific instructions.

Safety data for Nitrofurantoin in pregnancy are limited; it is generally avoided during the first trimester and not recommended for routine use unless the benefits clearly outweigh the risks. Caution is also advised for breastfeeding mothers, and a healthcare professional should evaluate the risk‑benefit profile.

Submit an inquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with agents such as trimethoprim‑sulfamethoxazole or fluoroquinolones, Nitrofurantoin offers a narrow spectrum focused on common uropathogens and a lower propensity for promoting resistance. However, it is contraindicated in patients with significant renal impairment, whereas some alternatives may be used in that population.

Store Nitrofurantoin at below 25 °C in the original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not use the product if it shows signs of damage, discoloration or compromised integrity.

Nitrofurantoin is taken orally, usually with food or a full glass of water to improve absorption and reduce gastrointestinal irritation. The tablet should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse reactions can include pulmonary toxicity (acute or chronic lung disease), severe hepatic injury, hemolytic anemia especially in patients with G6PD deficiency, and peripheral neuropathy. Prompt medical attention is required if symptoms such as shortness of breath, jaundice, dark urine or numbness develop.

Patients with severe renal impairment (creatinine clearance below 30 mL/min), known hypersensitivity to nitrofurantoin or other nitrofurans, and those with a history of pulmonary or hepatic reactions to the drug should avoid its use. A clinician must evaluate suitability before initiating therapy.